|
|
|
|
Research from National Taiwan University in lung cancer provides new insights
- (NewsRx.com) -- 'Malignant pleural effusions (MPEs) are often observed in lung cancer, especially adenocarcinoma (see also Lung Cancer).Epidermal growth factor receptor (EGFR) gene mutations are usually detected in lung ...
|
|
|
Adenocarcinoma - Research from Cornell University yields new data on adenocarcinoma
Medical Devices & Surgical Technology Week Welcome to NewsRx!Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week We're a pay-per-view site for premium content! If you'd like to...
|
|
|
Adenocarcinoma - Study findings on adenocarcinoma are outlined in reports from T.A.N. Tran and colleagues
'A typical/florid mesothelial associated with another process is not an infrequent phenomenon and has been reported in a variety of tumors.In those instances, the mesothelial proliferation might create a misdiagnosis of but seldom raises...
|
|
|
Data on pancreatic cancer detailed by researchers at Innsbruck Medical University
- (NewsRx.com) -- According to a study from Innsbruck, Austria, 'Pancreatic cancer is one of the most devastating human malignancies (see also Pancreatic Cancer).Despite considerable research efforts, it remains resistant to almost all...
|
|
|
Research in the area of cancer reported from University of Sao Paulo
- (NewsRx.com) -- 'Differently graded areas of human prostate adenocarcinoma were examined after Masson's trichrome staining or immunohistochemistry for smooth muscle alpha-actin, type IV collagen and laminin (see also Cancer).In...
|
|
|
Researchers at Mater Misericordiae University have published new data on gastric cancer
- (NewsRx.com) -- According to a study from Dublin, Ireland, 'The most lethal aspects of gastric adenocarcinoma (GA) are its invasive and metastatic properties (see also Gastric Cancer).This aggressive phenotype remains poorly...
|
|
|
Helix BioPharma Presents Preclinical L-DOS47 Data at The Second Conference of Lung Cancer in Warsaw, Poland
Presentation to Highlight Mechanism by which L-DOS47 Targets the Cellular Microenvironment to Debilitate and Destroy Lung Adenocarcinoma Cells AURORA, Ontario, Nov.19 /PRNewswire/ -- Helix BioPharma Corp. today announced that it...
|
|
|
Diagnostic challenge in autoimmune pancreatitis: beware of shipwreck!
Service de Pancratologie-Gastroentrologie, Ple des Maladies de l'Appareil Digestif, Hpital Beaujon, Clichy Cedex, France Correspondence to: Professor Philippe Lvy, Service de Pancratologie-Gastroentrologie, Ple des Maladies de l'Appareil...
|
|
|
[18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Respons
Sohn HJ et al.- FLT-PET can predict response to gefitinib 7 days after treatment in nonsmokers with advanced adenocarcinoma of the lung. The change in tumor SUVmax obtained by FLT-PET seems to be a promising predictive variable.
|
|
|
Evaluation of lung tumor perfusion by dynamic contrast-enhanced MRI
Pauls S et al.- Results indicate that dynamic contrast enhanced MRI might become instrumental in differentiating benign from malignant intrapulmonary tumors and distinguishing adenocarcinoma from squamous cell carcinoma.
|
|
|
Taxotere Breast Cancer Drug Withdrawn From EMEA Consideration
It looks like French pharma company, sanofi-aventis, has decided to withdraw an application to the EU regulators to extend the indications on the cancer drug Taxotere and its generic version, Docetaxel Winthrop.The European Medicines...
|
|
|
SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor
DUBLIN, Calif.SuperGen will initiate a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic profile of SGI-1776, a novel, orally administered, small molecule anticancer compound. The first in human clinical...
|
|
|
SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor
DUBLIN, Calif., Nov.20 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that it has received clearance to initiate...
|
|
|
[Thoracic Oncology] Effect of BRCA1 Haplotype on Survival of Non-Small-Cell Lung Cancer Patients Treated With
BRCA1 Haplotype on Survival of Non-Small-Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy -- Kim et al., 10.1200/JCO.2008.16.6496 -- Journal of Clinical OncologySearch for: Limit by: All Topics Original Reports Review...
|
|
|
Smoking, alcohol consumption linked to cancer risk
alcohol consumption linked to cancer risk HemOncToday Welcome, Guest Posted November 18, 2008 , alcohol consumption linked to cancer risk AACR Frontiers in Cancer Prevention Research Researchers from the Netherlands have found an association...
|
|
|
Helix BioPharma Presents Preclinical L-DOS47 Data at The Second Conference of Lung Cancer in Warsaw, Poland
Presentation to Highlight Mechanism by which L-DOS47 Targets the Cellular Microenvironment to Debilitate and Destroy Lung Adenocarcinoma Cells AURORA, Ontario, Nov.19 /PRNewswire/ -- Helix BioPharma Corp. today announced that it...
|
|
|
Helix BioPharma Presents Preclinical L-DOS47 Data at The Second Conference of Lung Cancer in Warsaw, Poland
Presentation to Highlight Mechanism by which L-DOS47 Targets the Cellular Microenvironment to Debilitate and Destroy Lung Adenocarcinoma Cells AURORA, Ontario, Nov.19 /PRNewswire/ -- Helix BioPharma Corp. today announced that it...
|
|
|
Helix BioPharma Presents Preclinical L-DOS47 Data at The Second Conference of Lung Cancer in Warsaw, Poland
Presentation to Highlight Mechanism by which L-DOS47 Targets the Cellular Microenvironment to Debilitate and Destroy Lung Adenocarcinoma Cells << >> AURORA, Ontario, Nov.19 /PRNewswire/ -- Helix BioPharma Corp. (TSX,...
|
|
|
Helix BioPharma Presents Preclinical L-DOS47 Data at The Second Conference of Lung Cancer in Warsaw, Poland
Presentation to Highlight Mechanism by which L-DOS47 Targets the Cellular Microenvironment to Debilitate and Destroy Lung Adenocarcinoma Cells AURORA, Ontario, Nov.19 /PRNewswire/ -- Helix BioPharma Corp. today announced that it...
|
|
|
Helix BioPharma Presents Preclinical L-DOS47 Data at The Second Conference of Lung Cancer in Warsaw, Poland
Presentation to Highlight Mechanism by which L-DOS47 Targets the Cellular Microenvironment to Debilitate and Destroy Lung Adenocarcinoma Cells << >> AURORA, Ontario, Nov.19 /PRNewswire/ -- Helix BioPharma Corp. (TSX,...
|
|
|
Helix BioPharma Presents Preclinical L-DOS47 Data at The Second Conference of Lung Cancer in Warsaw, Poland
resentation to Highlight Mechanism by which L-DOS47 Targets the Cellular Microenvironment to Debilitate and Destroy Lung Adenocarcinoma Cells AURORA, Ontario, Nov.19 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: 'HBP') today...
|
|
|
Helix BioPharma Presents Preclinical L-DOS47 Data at The Second Conference of Lung Cancer in Warsaw, Poland
AURORA, Ontario, Nov.19 Helix-BioPharma-DOS47 Presentation to Highlight Mechanism by which L-DOS47 Targets the Cellular Microenvironment to Debilitate and Destroy Lung Adenocarcinoma Cells AURORA, Ontario, Nov. 19 /PRNewswire/ --...
|
|
|
Helix BioPharma Presents Preclinical L-DOS47 Data at The Second Conference of Lung Cancer in Warsaw, Poland
Presentation to Highlight Mechanism by which L-DOS47 Targets the Cellular Microenvironment to Debilitate and Destroy Lung Adenocarcinoma Cells AURORA, Ontario, Nov.19 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: 'HBP') today...
|
|
|
Helix BioPharma Presents Preclinical L-DOS47 Data at The Second Conference of Lung Cancer in Warsaw, Poland
Presentation to Highlight Mechanism by which L-DOS47 Targets the Cellular Microenvironment to Debilitate and Destroy Lung Adenocarcinoma Cells AURORA, Ontario, Nov.19 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: 'HBP') today...
|
|
|
Helix BioPharma Presents Preclinical L-DOS47 Data at The Second Conference of Lung Cancer in Warsaw, Poland
Presentation to Highlight Mechanism by which L-DOS47 Targets the Cellular Microenvironment to Debilitate and Destroy Lung Adenocarcinoma Cells AURORA, Ontario, Nov.19 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: 'HBP') today...
|
